The strengths of the current study include the following: (1) the use of comprehensive neuropsychological assessments to diagnose cognitive impairment and dementia properly; (2) the use of well-established neuroimaging measurements for amyloid and CeVD pathology; and (3) the inclusion of covariates such as age, gender, education, and APOE ε4 carrier. The gene discussed is APOE; the disease is Cognitive impairment.